See today's BioWorld
To read the full story, subscribe or sign in.

Sichuan's Hinova raises $40M in series B to advance prostate cancer drug to phase III testing

Aug. 1, 2019
By Elise Mak
HONG KONG – Chengdu-based Hinova Pharmaceuticals Inc., of China's Sichuan province, closed a series B financing that added $40 million to the company's pocket. 
BioWorld